Topiroxostat

Drug Profile

Topiroxostat

Alternative Names: FYX-051; SK-0910; Topiroric; Uriadec

Latest Information Update: 01 May 2015

Price : $50

At a glance

  • Originator Fuji Yakuhin
  • Developer Fuji Yakuhin; Sanwa Kagaku Kenkyusho
  • Class Nitriles; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Xanthine dehydrogenase inhibitors; Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gout; Hyperuricaemia
  • Phase II Diabetic nephropathies

Most Recent Events

  • 01 Mar 2015 Phase-II clinical trials in Diabetic nephropathies in Japan (PO) (NCT02327754)
  • 01 Mar 2015 Sanwa Kagaku Kenkyusho and Fuji Yakuhin initiate enrolment in a phase II trial for Gout in Japan (NCT02327754)
  • 24 Dec 2014 Sanwa Kagaku Kenkyusho and Fuji Yakuhin plan a phase IIa trial in patients with diabetic nephropathy and hyperuricaemia, with or without Gout, in Japan (NCT02327754)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top